ATE433448T1 - Kondensierte heterocyclen und deren verwendungen - Google Patents

Kondensierte heterocyclen und deren verwendungen

Info

Publication number
ATE433448T1
ATE433448T1 AT04717339T AT04717339T ATE433448T1 AT E433448 T1 ATE433448 T1 AT E433448T1 AT 04717339 T AT04717339 T AT 04717339T AT 04717339 T AT04717339 T AT 04717339T AT E433448 T1 ATE433448 T1 AT E433448T1
Authority
AT
Austria
Prior art keywords
condensed heterocycles
heterocycles
condensed
Prior art date
Application number
AT04717339T
Other languages
English (en)
Inventor
Brian Aquila
Michael Block
Audrey Davies
Jayachandran Ezhuthachan
Sandra Filla
Richard Luke
Timothy Pontz
Maria-Elena Theoclitou
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0300627A external-priority patent/SE0300627D0/xx
Priority claimed from SE0301138A external-priority patent/SE0301138D0/xx
Priority claimed from SE0301697A external-priority patent/SE0301697D0/xx
Priority claimed from SE0302826A external-priority patent/SE0302826D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE433448T1 publication Critical patent/ATE433448T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04717339T 2003-03-07 2004-03-04 Kondensierte heterocyclen und deren verwendungen ATE433448T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0300627A SE0300627D0 (sv) 2003-03-07 2003-03-07 Novel fused heterocycles and uses therof
SE0301138A SE0301138D0 (sv) 2003-04-15 2003-04-15 Novel fused heterocycles and uses thereof
SE0301697A SE0301697D0 (sv) 2003-06-10 2003-06-10 Novel fused heterocycles and uses thereof
SE0302826A SE0302826D0 (sv) 2003-10-24 2003-10-24 Novel fused heterocycles and uses thereof
PCT/SE2004/000304 WO2004078758A1 (en) 2003-03-07 2004-03-04 Novel fused heterocycles and uses thereof

Publications (1)

Publication Number Publication Date
ATE433448T1 true ATE433448T1 (de) 2009-06-15

Family

ID=32966643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04717339T ATE433448T1 (de) 2003-03-07 2004-03-04 Kondensierte heterocyclen und deren verwendungen

Country Status (24)

Country Link
US (1) US20060270689A1 (de)
EP (1) EP1601673B1 (de)
JP (2) JP3947758B2 (de)
KR (1) KR20050107784A (de)
AR (1) AR043487A1 (de)
AT (1) ATE433448T1 (de)
AU (1) AU2004218080B2 (de)
BR (1) BRPI0408150A (de)
CA (1) CA2518224C (de)
CY (1) CY1109300T1 (de)
DE (1) DE602004021477D1 (de)
DK (1) DK1601673T3 (de)
ES (1) ES2326647T3 (de)
IS (1) IS8036A (de)
MX (1) MXPA05009577A (de)
MY (1) MY141583A (de)
NO (1) NO20054340L (de)
NZ (1) NZ542227A (de)
PL (1) PL1601673T3 (de)
PT (1) PT1601673E (de)
SI (1) SI1601673T1 (de)
TW (1) TW200510427A (de)
UA (1) UA81470C2 (de)
WO (1) WO2004078758A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
EP1503993A4 (de) 2002-05-09 2006-05-03 Cytokinetics Inc Verbindungen, verfahren und zusammensetzungen
JP2005530785A (ja) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
EP1513820A4 (de) 2002-05-23 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
EP1556357A4 (de) 2002-06-14 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
JP2006501306A (ja) 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
CA2518465A1 (en) * 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
JP2007513154A (ja) 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
BRPI0514390A (pt) * 2004-08-18 2008-06-10 Astrazeneca Ab enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
RU2007109867A (ru) * 2004-08-18 2008-09-27 Астразенека Аб (Se) Выбранные конденсированные гетероциклы и их применение
EP1856128A4 (de) * 2005-01-19 2009-12-23 Merck & Co Inc Inhibitoren von mitotischem kinesin
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
DE102005027168A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
ES2564826T3 (es) 2007-06-21 2016-03-29 Neuronascent, Inc. Métodos y composiciones para estimular neurogénesis e inhibir degeneración neuronal utilizando isotiazolopirimidinonas
WO2009001214A2 (en) * 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
CN114478429B (zh) * 2020-11-13 2023-11-17 中国科学院大连化学物理研究所 一种3-烷硫基异噻唑衍生物及其合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
NZ526622A (en) * 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
US6809102B2 (en) * 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AU2002363429B2 (en) * 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
AU2002363960B2 (en) * 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US7378411B2 (en) * 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
WO2003049679A2 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE424388T1 (de) * 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
CA2467726A1 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
DE60333094D1 (de) * 2002-04-17 2010-08-05 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
JP2005530785A (ja) * 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
EP1503993A4 (de) * 2002-05-09 2006-05-03 Cytokinetics Inc Verbindungen, verfahren und zusammensetzungen
EP1513820A4 (de) * 2002-05-23 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
EP1539727B1 (de) * 2002-07-17 2009-02-18 Cytokinetics, Inc. Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
EP1636225B1 (de) * 2003-06-20 2010-02-24 Novartis Vaccines and Diagnostics, Inc. Pyridino¬1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs
EP1670456A2 (de) * 2003-10-06 2006-06-21 Cytokinetics, Inc. Verbindungen, zusammensetzungen und verfahren
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
PT1732926E (pt) * 2004-04-06 2009-04-03 Novartis Vaccines & Diagnostic Inibidores de cinesinas mitóticas
EP1807399A2 (de) * 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Indol- und benzimidazolderivate

Also Published As

Publication number Publication date
BRPI0408150A (pt) 2006-03-21
JP2007063257A (ja) 2007-03-15
WO2004078758A1 (en) 2004-09-16
IS8036A (is) 2005-09-19
JP3947758B2 (ja) 2007-07-25
NZ542227A (en) 2008-12-24
DK1601673T3 (da) 2009-08-24
PT1601673E (pt) 2009-07-29
TW200510427A (en) 2005-03-16
AR043487A1 (es) 2005-08-03
UA81470C2 (en) 2008-01-10
EP1601673B1 (de) 2009-06-10
CA2518224A1 (en) 2004-09-16
CY1109300T1 (el) 2014-07-02
US20060270689A1 (en) 2006-11-30
PL1601673T3 (pl) 2009-10-30
SI1601673T1 (sl) 2009-10-31
EP1601673A1 (de) 2005-12-07
CA2518224C (en) 2010-06-15
MXPA05009577A (es) 2005-12-12
DE602004021477D1 (de) 2009-07-23
KR20050107784A (ko) 2005-11-15
JP2006519853A (ja) 2006-08-31
NO20054340L (no) 2005-09-26
ES2326647T3 (es) 2009-10-16
HK1084390A1 (en) 2006-07-28
AU2004218080B2 (en) 2008-01-03
AU2004218080A1 (en) 2004-09-16
MY141583A (en) 2010-05-14

Similar Documents

Publication Publication Date Title
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
CY2018009I2 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
DE602004021477D1 (de) Kondensierte heterocyclen und deren verwendungen
CY2016027I2 (el) Πολυμερικες ενωσεις πολυαλκυλενιου και χρησεις αυτων
DE60326611D1 (de) N und dergleichen
NL1025404A1 (nl) Pyrazolo-triazine verbindingen en gebruik daarvan.
DE60316643D1 (de) Gleitlager und damit versehene Lagervorrichtung
DE60237726D1 (de) Roll-/Gleitelement und Rollvorrichtung
DE60321401D1 (de) Demodulationseinrichtung und demodulationsverfahren
DE502004009028D1 (de) Scheinwerfer und Scheinwerferelement
DE10397002A5 (de) Biosensor, Biosensorchip und Biosensoreinrichtung
DE60328206D1 (de) Scheibenwaschanlagendüse und scheibenwaschanlage
DE602004030044D1 (de) Bacillus thuringiensis und deren verwendungen
DE60316588D1 (de) Neue lactame und deren verwendungen
DE60331729D1 (de) Audiocodierungsverfahren und audiocodierungseinrichtung
DK1675852T3 (da) Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
DE60333629D1 (de) Neue phospholipasen und deren verwendungen
DE60303480D1 (de) Sensorenanordnung und Halteklammer dafür
ATE371653T1 (de) Benzoxazinderivate und deren verwendungen
DE60304229D1 (de) Pinselabflacher und mit Pinselabflacher ausgerüstete Zeichenvorrichtung
EP1583528A4 (de) Nf-kb inhibitoren und ihre verwendungen
ATE446301T1 (de) Ausgewählte kondensierte heterocyclen und deren anwendung
DE602004032139D1 (de) Festes schmiermittel und gleitglied
EP1812055A4 (de) Chlamydien-antigene und ihre verwendungen
EP1687398A4 (de) Hiv-abhängige expressionskonstrukte und verwendungen dafür

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1601673

Country of ref document: EP